Trials / Completed
CompletedNCT04586907
A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3537021 in Healthy Participants and Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 85 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 21 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to learn more about the safety of LY3537021 and any side effects that might be associated with it in healthy participants and participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to check how much LY3537021 gets into the bloodstream and how long the body takes to eliminate it. This study will last up to about 19 weeks including screening period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3537021 | Administered SC. |
| DRUG | Placebo | Administered SC. |
Timeline
- Start date
- 2020-11-23
- Primary completion
- 2021-11-30
- Completion
- 2021-11-30
- First posted
- 2020-10-14
- Last updated
- 2021-12-17
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT04586907. Inclusion in this directory is not an endorsement.